Calidi Biotherapeutics (CLDI) Common Equity (2021 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Common Equity of $3.8 million for Q4 2025, up 145.05% year-over-year from $1.5 million in Q4 2024, and down 45.66% quarter-over-quarter from $6.9 million in Q3 2025.
Calidi Biotherapeutics (CLDI) Common Equity (2021 - 2026) Analysis & Trends
Calidi Biotherapeutics' Common Equity history runs 5 years deep, the most recent figure standing at $3.8 million for Q4 2025.
- In Q4 2025, Common Equity rose 145.05% year-over-year to $3.8 million; the TTM figure through Dec 2025 stood at $3.8 million (up 145.05% YoY), while the FY2025 annual figure was $3.8 million, up 145.05% from the prior year.
- Common Equity for Q4 2025 stood at $3.8 million, down from $6.9 million in the prior quarter.
- The five-year high for Common Equity was $7.3 million in Q1 2025, with the low at -$63.7 million in Q2 2023.
- The 5-year median for Common Equity is -$11.8 million (2024), against an average of -$20.3 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity sank 795.61% in 2024, then surged 170.61% in 2025.
- Calidi Biotherapeutics' Common Equity stood at -$31.6 million in 2021, then tumbled by 59.56% to -$50.4 million in 2022, then surged by 83.67% to -$8.2 million in 2023, then surged by 118.63% to $1.5 million in 2024, then jumped by 145.05% to $3.8 million in 2025.
- Business Quant data shows CLDI's Common Equity at $3.8 million in Q4 2025, $6.9 million in Q3 2025, and $2.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 9.79 Bn |
| 10 | Calidi Biotherapeutics | 1.98 Mn | -2.12 Mn | - | 3.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.13 Mn |
| Dec 31, 2025 | 3.76 Mn |
| Sep 30, 2025 | 6.92 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 7.30 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | -9.80 Mn |
| Jun 30, 2024 | -11.75 Mn |
| Mar 31, 2024 | -14.57 Mn |
| Dec 31, 2023 | -8.24 Mn |
| Sep 30, 2023 | -1.09 Mn |
| Jun 30, 2023 | -63.71 Mn |
| Mar 31, 2023 | -55.10 Mn |
| Dec 31, 2022 | -50.44 Mn |
| Sep 30, 2022 | -43.93 Mn |
| Jun 30, 2022 | -39.64 Mn |
| Mar 31, 2022 | -37.62 Mn |
| Dec 31, 2021 | -31.61 Mn |